Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

• Results Overview

  The oral medication abrocitinib taken once daily was effective in treating moderate-to-severe eczema in both teens and adults, with higher doses showing better results than lower doses.

• Study Summary

  Num Participants:

  387

  Study Type:

  Rct

  Control Group:

  Placebo Once Daily

  Efficacy End Points Treatment:

  {'IGA response': 44, 'EASI-75': 63}

  Efficacy End Points Control:

  {'IGA response': 8, 'EASI-75': 12}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Any Adverse Event	Varies	78.0

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Any Adverse Event	Varies	57.0